Refine your search with filters

All-Materials All
Congress-AbstractsCongress Abstracts
Tools-SkillsTools & Skills
PublicationsPublications
Congress-SlidesCongress Presentations
Videos-PodcastsVideos & Podcasts

Quicksearch

P395: Etrolizumab demonstrated no difference among doses in symptomatic and endoscopic-based evaluation of remission in anti-TNF-α-naïve patients in a post-hoc analysis of the phase 2 ulcerative colitis trial (EUCALYPTUS)ECCO '17 Barcelona
Year: 2017
Authors:

Sandborn W.J.1, Schreiber S.2, Tang M.T.3, Tatro A.R.3, Oh Y.S.*3, Maciuca R.3

1University of California, San Diego, La Jolla, United States 2Kiel University, Kiel, Germany 3Genentech, South San Francisco, United States

P396: Long-term efficacy of thiopurines as maintenance treatment in 130 patients with ulcerative colitisECCO '17 Barcelona
Year: 2017
Authors:

Lefevre C., Fotsing G., Wangermez M., Beau P.

CHU Poitiers, Poitiers, France

P397: Approach and management of psychological aspects of inflammatory bowel disease described by patients and physicians in Spain. The ENMENTE ProjectECCO '17 Barcelona
Year: 2017
Authors:

Marín-Jiménez I.*1, Panadero A.2, Gobbo Montoya M.3, Cañas M.4, Modino Y.5, Guardiola J.6, Cea-Calvo L.7, Juliá B.7, Romero C.7, Carmona L.8, Barreiro-de Acosta M.9

1Hospital Gregorio Marañόn, Unidad de Enfermedad Inflamatoria Intestinal, Servicio de Aparato digestivo e Instituto de Investigaciόn Sanitaria Gregorio Marañόn (IiSGM), Madrid, Spain 2Asociaciόn de Enfermos de Crohn y Colitis Ulcerosa de Madrid (ACCU Madrid), Psicόlogo especializado en Enfermedad Inflamatoria Intestinal, Madrid, Spain 3Positivamente, Centro de Psicología, Madrid, Spain 4Hospital Clínico San Carlos, Unidad de Enfermedad Inflamatoria Intestinal, Servicio de Aparato Digestivo, Madrid, Spain 5Confederaciόn de Asociaciones de pacientes de enfermos de Crohn y Colitis Ulcerosa de España (ACCU España), Madrid, Spain 6Hospital Universitari de Bellvitge-IDIBELL, Unidad de Enfermedad Inflamatoria Intestinal, Servicio de Aparato Digestivo, L'Hospitalet de Llobregat, Barcelona, Spain 7Merck Sharp & Dohme de España, Medical Affairs, Madrid, Spain 8Instituto de Salud Musculoesquelética, InMusc, Madrid, Spain 9Complexo Universitario de Santiago de Compostela, Unidad de Enfermedad Inflamatoria Intestinal, Servicio de Aparato Digestivo, Santiago de Compostela, Spain

P398: An objective measure of response to treatment for patients with Crohn's perianal fistulas on anti-TNF treatmentECCO '17 Barcelona
Year: 2017
Authors:

Sahnan K.*1, Lung P.F.2, Adegbola S.O.1, Burling D.2, Burn J.2, Tozer P.J.1, Gupta A.2, Faiz O.D.1, Phillips R.K.1, Hart A.L.3

1St Mark's Hospital, Colorectal Surgery, London, United Kingdom 2St Mark's Hospital, Gastrointestinal Imaging, London, United Kingdom 3St Mark's Hospital, IBD/Physiology, London, United Kingdom

P399: Adverse events associated with azathioprine treatment in Korean pediatric inflammatory bowel disease patientsECCO '17 Barcelona
Year: 2017
Authors:

Kim M.

Inje University College of Medicine, Ilsan Paik Hospital, Pediatrics, Goyang-si, Gyeonggi-do, South Korea

P400: Risk-adjusted use of thiopurines prevented surgical recurrence in patients with Crohn's disease after intestinal resectionECCO '17 Barcelona
Year: 2017
Authors:

Guo J.1, Mao R.1, Luo X.1, Ben Horin S.1,2, Chen M.*3

1The first affiliated hospital of Sun Yat-Sen University, Department of Radiology, Guangzhou, China 2Sheba Medical Center, Department of Gastroenterology, Tel Hashomer, Israel 3The first affiliated hospital of Sun Yat-Sen University, Department of Gastroenterology, Guangzhou, China

P401: Anti-TNF treatments in Crohn's disease and improvement in work productivity and quality of life: an observational study from TurkeyECCO '17 Barcelona
Year: 2017
Authors:

Törüner M.*1, Başaranoğlu M.2, Atuğ Ö.3, Şentürk Ö.4, Akyüz F.5, Ünsal B.6, Över Hamzaoğlu H.7, Tekin F.8, Sezgin O.9, Akpınar H.10, Çelik A.F.11, Tezel A.12, Göktürk H.S.13, Kav T.14

1Ankara University School of Medicine, Gastroenterology, Ankara, Turkey 2Bezmialem Vakif University Faculty of Medicine, Gastroenterology, Istanbul, Turkey 3Marmara University School of Medicine, Gastroenterology, Istanbul, Turkey 4Kocaeli University Faculty of Medicine, Gastroenterology, Izmit, Turkey 5Istanbul University Istanbul Faculty of Medicine, Gastroenterology, Istanbul, Turkey 6Izmir Katip Celebi University, Gastroenterology, Izmir, Turkey 7Acıbadem Fulya Hospital, Gastroenterology, Istanbul, Turkey 8Ege University Medical School, Gastroenterology, Izmir, Turkey 9Mersin University Faculty of Medicine, Gastroenterology, Mersin, Turkey 10Dokuz Eylul University Faculty of Medicine, Gastroenterology, Izmir, Turkey 11Istanbul University Cerrahpasa Medical School, Gastroenterology, Istanbul, Turkey 12Trakya University Faculty of Medicine, Gastroenterology, Edirne, Turkey 13Baskent University Faculty of Medicine, Gastroenterology, Konya, Turkey 14Hacettepe University School of Medicine, Gastroenterology, Ankara, Turkey

P402: Discontinuation of short-term infliximab maintenance therapy in patients with Crohn's disease: outcomes and risk factors associated with relapseECCO '17 Barcelona
Year: 2017
Authors:

Zheng D.1, Mao R.1, Chen B.1, Feng T.1, Ben-Horin S.2, Chen M.*1

1The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China 2Tel-Aviv University, Tel-Aviv, Israel

P403: Golimumab therapy for ulcerative colitis – an Irish multicentre experienceECCO '17 Barcelona
Year: 2017
Authors:

O'Connell J.*1, Rowan C.2, Chan G.3, Harkin G.4, Parihar V.5, Layden J.3, Patchett S.5, Stack R.6, MacMathuna P.3, O'Toole A.5, Ryan B.7, MacCarthy F.1, McKiernan S.1, Doherty G.2, Eagan L.4, Kevans D.1

1St James Hospital, Gastroenterology, Dublin, Ireland 2St Vincent's University Hospital, Center for Colorectal Disease, Dublin, Ireland 3Mater Misericordiae University Hospital, Department of Gastroenterology, Dublin, Ireland 4University College Hospital Galway, Department of Gastroenterology, Galway, Ireland 5Beaumont Hospital, Department of Gastroeneterology, Dublin, Ireland 6Adelaide & Meath Hospital, Dublin, Incorporating The National Children's Hospital, Department of Gastroenterology, Level 2, Dublin, Ireland 7Adelaide & Meath Hospital, Dublin, Incorporating The National Children's Hospital, Department of Gastroenterology, Dublin, Ireland

P404: Vaccinations and immunization status in Paediatric inflammatory bowel disease: data from the VIP IBD studyECCO '17 Barcelona
Year: 2017
Authors:

Martinelli M.*1, Strisciuglio C.2, Giugliano F.P.3, Urbonas V.4, Serban D.5, Banaszkiewicz A.6, Assa A.7, Drskova T.8, Hojsak I.9, Navas Lopez V.M.10, Romano C.11, Sladek M.12, Aloi M.13, Kucinskiene R.14, Staiano A.15, Miele E.15 ESPGHAN Open IBD Interest Group16

1University of Naples “Federico II”, Translational Medical Science, Section of Pediatrics, Naples, Italy 2Second University of Naples, Naples, Italy 3University of Naples, Naples, Italy 4Vilnius University Clinic of Children's Diseases, Vilnius University, Vilnius, Lithuania 5University of Medicine and Pharmacy Iuliu Hatieganu, Cluj–Napoca, Romania, Cluj Napoca, Romania 6Medical University of Warsaw, Paediatric Gastroenterology and Nutrition, Warsaw, Poland 7Institute of Gastroenterology, Nutrition and Liver Diseases, Schneider Children's Medical Center of Israel, Petach-Tikva, Israel; and Sackler Faculty of Medicine, Tel-Aviv University,Tel Aviv, Israel 8Charles University, Prague, Czech Republic 9Referral Center for Pediatric Gastroenterology and Nutrition, Children's Hospital Zagreb, Zagreb, Croatia 10Hospital Materno Infantil, Avda. Arroyo de los ángeles s/n, 29011, Pediatric Gastroenterology and Nutrition Unit, Malaga, Spain 11University of Messina, Messina, Italy 12Department of Pediatrics, Gastroenterology and Nutrition Jagiellonian University School of Medicine, Cracow, Poland 13Sapienza University, Rome, Italy 14Department of Gastroenterology, Medical Academy, Lithuanian University of Health Sciences, Kaunas, Lithuania 15University of Naples “Federico II”, Naples, Italy 16University of Naples, Translational Medical Science, Section of Pediatrics, Naples, Italy

P405: Toxicity of thiopurines in patients with inflammatory bowel disease: inventory and predictive factorsECCO '17 Barcelona
Year: 2017
Authors:

Labidi A., Serghini M., Ben Mustapha N., Fekih M., Boubaker J., Filali A.

La Rabta University Hospital, Gastroenterology, Tunis, Tunisia

P406: Clinical correlations of infliximab trough levels and antibodies to infliximab in Korean patients with Crohn's diseaseECCO '17 Barcelona
Year: 2017
Authors:

Oh E.H.*1, Ko D.-H.2, Seo H.3, Chang K.3, Kim G.-U.3, Song E.M.3, Seo M.3, Lee H.-S.4, Hwang S.W.3,5, Yang D.-H.3, Ye B.D.3,5, Byeon J.-S.3, Myung S.-J.3, Yang S.-K.3,5, Park S.H.3,5

1University of Ulsan College of Medicine, Asan Medical Center, Department of Internal Medicine, Seoul, South Korea 2Hallym University College of Medicine, Dongtan Sacred Heart Hospital, Department of Laboratory Medicine, Hwaseong, South Korea 3University of Ulsan College of Medicine, Asan Medical Center, Department of Gastroenterology, Seoul, South Korea 4University of Ulsan College of Medicine, Asan Medical Center, Health Screening and Promotion Center, Seoul, South Korea 5Asan Medical Center, University of Ulsan College of Medicine, Inflammatory Bowel Disease Center, Seoul, South Korea

P407: Prospective evaluation of clinical efficacy and safety of golimumab in biologic experienced and naïve patients with moderate to severe ulcerative colitis: experience from a tertiary referral centreECCO '17 Barcelona
Year: 2017
Authors:

Orlandini B., Dragoni G., Bagnoli S., Deiana S., Macrì G., Rogai F.

Careggi, Gastroenterology, Florence, Italy

P408: Long-term efficacy of infliximab in patients with ulcerative colitis – an observational study from a single center in NorwayECCO '17 Barcelona
Year: 2017
Authors:

Lerang F., Henriksen M., Jelsness-Jørgensen L.-P.

Central Hospital of Østfold, Medical, Sarpsborg, Norway

P409: Mesalamine enemas for induction of remission in pediatric ulcerative colitis refractory to oral mesalamine: a prospective cohort studyECCO '17 Barcelona
Year: 2017
Authors:

Levine A.*1, Yerushalmi B.2, Kori M.3, Broide E.4, Mozer-Glassberg Y.5, Shaoul R.6, Kolho K.-L.7, Shteyer E.8, Shamaly H.9, Ledder O.10, Cohen S.11, Peleg S.12, Sarbagili-Shabat C.1, Focht G.10, Shachmon E.10, Boaz M.13, On A.14, Turner D.10

1Paediatric and Gastroenterology and Nutrition Unit, Wolfson Medical Center, Tel Aviv University, Holon, Israel 2Soroka University Medical Center and Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel 3Kaplan Hospital, Rehovot, Israel 4Assaf Harofeh Medical Center, Tel Aviv, Israel 5Schneider's Children Hospital, Peatach Tikva, Israel 6Rambam Medical Center, Haifa, Israel 7Children's Hospital and Helsinki University, Helsinki, Finland 8Hadassah Medical Center, Jerusalem, Israel 9French Hospital, Nazareth Hospital, Israel 10Juliet Keidan Institute of Paediatric Gastroenterology, Shaare Zedek Medical Center, The Hebrew University of Jerusalem, Jerusalem, Israel 11Tel Aviv Medical Center, Tel Aviv University, Tel Aviv, Israel 12Haemek Hospital, Afula, Israel 13Department of Nutrition Sciences, Ariel University; Epidemiology and Research Unit, E. Wolfson Medical Center, Holon, Israel 14Poriah Hospital, Tiberius, Israel and Bar-Ilan University, The faculty of medicine in the Galilee, Sefad, Israel

P410: Vedolizumab is safe and effective for IBD, but has no effect on liver biochemistry in patients with concurrent PSCECCO '17 Barcelona
Year: 2017
Authors:

Christensen B.*1, Micic D.2, Gibson P.R.1, Singh S.3, Bellaguarda E.2, Corsello P.4, Gaetano J.N.5, Kinnucan J.4, Rao V.L.5, Reddy S.2, Yarur A.3, Rubin D.T.5, Pekow J.5

1Alfred Hospital and Monash University, Melbourne, Australia 2Northwestern University Feinberg School of Medicine, Chicago, United States 3Medical College of Wisconsin, Wisconsin, United States 4University of Michigan Health System, Ann Arbor, United States 5University of Chicago Medicine, Inflammatory Bowel Disease Center, Chicago, United States

P411: Drug persistence and need for dose intensification to adalimumab therapy; the importance of therapeutic drug monitoring in inflammatory bowel diseasesECCO '17 Barcelona
Year: 2017
Authors:

Kurti Z.*1, Rutka M.2, Vegh Z.1, Gonczi L.1, Farkas K.2, Lovasz B.D.1, Gecse K.B.1, Golovics P.A.1, Szalay B.3, Molnar T.2, Lakatos P.L.1

1Semmelweis University, First Department of Medicine, Budapest, Hungary 2University of Szeged, First Department of Internal Medicine, Szeged, Hungary 3Semmelweis University, Department of Laboratory Medicine, Budapest, Hungary

P412: The Sicilian network of biological therapy in inflammatory bowel disease: preliminary data on efficacyECCO '17 Barcelona
Year: 2017
Authors:

Orlando A.1, Macaluso F.S.*1, Fries W.2, Privitera A.C.3, Cappello M.4, Siringo S.5, Inserra G.6, Magnano A.7, Di Mitri R.8, Belluardo N.9, Scarpulla G.10, Magrì G.11, Trovatello N.12, Carroccio A.13, Genova S.14, Calandruccio G.15, Vassallo R.16, Romano C.17, Pellegrino S.17, Citrano M.18, Accomando S.19, Ventimiglia M.1, Renna S.1, Orlando R.1, Rizzuto G.1, Vinci E.1, Cottone M.1

1Division of Internal Medicine, “Villa Sofia-Cervello” Hospital, Palermo, Italy 2Inflammatory bowel disease Unit, A.O.U. Policlinico “G. Martino”, Messina, Italy 3IBD Unit, A.O. “Cannizzaro”, Catania, Italy 4Gastroenterology and Hepatology Unit, A.O.U. Policlinico “G. Giaccone”, Palermo, Italy 5Gastroenterology Unit, A.R.N.A.S. “Garibaldi”, Catania, Italy 6Internal Medicine Unit, A.O.U. Policlinico “Vittorio Emanuele”, Catania, Italy 7Gastroenterology Unit, A.O.U. Policlinico “Vittorio Emanuele”, Catania, Italy 8Gastroenterology and endoscopy Unit, A.R.N.A.S. “Civico Di Cristina Benfratelli”, Palermo, Italy 9Gastroenterology Unit, A.O. “Guzzardi”, Vittoria, Italy 10Gastroenterology Unit, A.O.O.R. “S. Elia- M. Raimondi”, Caltanissetta, Italy 11Gastroenterology Unit, A.O. “Santa Marta e S. Venera”, Acireale, Italy 12Surgery Unit, A.O. “Umberto I”, Siracusa, Italy 13Internal Medicine Unit, A.O. “Giovanni Paolo II”, Sciacca, Italy 14Gastroenterology and Endoscopy Unit, A.O. “S. Antonio Abate”, Trapani, Italy 15Gastroenterology Unit, A.O.O.R. “Papardo Piemonte”, Messina, Italy 16Gastroenterology and Endoscopy Unit, A.O. “Buccheri La Ferla Fatebenefratelli”, Palermo, Italy 17Pediatric Gastroenterology Unit, A.O.U. Policlinico “G. Martino”, Messina, Italy 18Pediatric Unit, A.O.O.R. “Villa Sofia-Cervello”, Palermo, Italy 19Pediatric Unit, A.O.U. Policlinico “G. Giaccone”, Palermo, Italy

P413: Exclusive enteral nutrition provides an effective bridge to safer interval elective surgery for Crohn's diseaseECCO '17 Barcelona
Year: 2017
Authors:

Heerasing N.*1, Thompson B.1, Hendy P.1, Heap G.1,2, Walker G.1,2, Bethune R.1, Calvert C.1, Kennedy N.1,2, Ahmad T.1,2, Goodhand J.1,2

1Royal Devon & Exeter NHS Foundation Trust, Gastroenterology, Exeter, United Kingdom 2University of Exeter, Exeter, United Kingdom

P414: Vedolizumab in Pediatric inflammatory bowel diseases: a retrospective multi-center experience from the paediatric IBD Porto group of ESPGHANECCO '17 Barcelona
Year: 2017
Authors:

Ledder O.*1, de Meij T.2, Martín de Carpi J.3, Richmond L.4, Cohen S.5, Bronsky J.6, Shaoul R.7, Levine A.8, Escher J.9, deRidder L.9, Assa A.10, Ruemmele F.11, Shah N.12, Wolters V.13, Rodrigues A.14, Uhlig H.14, Urlep D.15, Posovsky C.16, Kolho K.17, Turner D.1

1Shaare Zedek Medical Center, Pediatric Gastroenterology, Jerusalem, Israel 2VU Medical Centre, Amsterdam, Netherlands 3Hospital Sant Joan de Deu, Barcelona, Spain 4Royal Hospital for Sick Children, Glasgow, United Kingdom 5Dana Medical Center, Tel Aviv, Israel 6University Hospital Motol, Prague, Czech Republic 7Rambam Medical Center, Haifa, Israel 8Wolfson Medical Center, Holon, Israel 9Erasmus Medical Center, Rotterdam, Netherlands 10Schneider Medical Center, Petach Tikva, Israel 11Hopital Necker Enfants Malades, Paris, France 12Great Ormond Street Hospital, London, United Kingdom 13University Medical Center Utrecht, Utrecht, Netherlands 14Oxford University Hospital, Oxford, United Kingdom 15Ljubljana University Medical Center, Ljubljana, Slovenia 16University Medical Center, Ulm, Germany 17Helsinki University Central Hospital, Helsinki, Finland